[go: up one dir, main page]

WO2016026014A8 - Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer - Google Patents

Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer Download PDF

Info

Publication number
WO2016026014A8
WO2016026014A8 PCT/BR2015/000127 BR2015000127W WO2016026014A8 WO 2016026014 A8 WO2016026014 A8 WO 2016026014A8 BR 2015000127 W BR2015000127 W BR 2015000127W WO 2016026014 A8 WO2016026014 A8 WO 2016026014A8
Authority
WO
WIPO (PCT)
Prior art keywords
acid derivative
perillic acid
pharmaceutical composition
cancer treatment
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2015/000127
Other languages
English (en)
French (fr)
Other versions
WO2016026014A1 (pt
Inventor
Antonio Carlos Siani
Maria Antonieta Ferrara
Paulo Sérgio Bergo DE LACERDA
Raquel Elisa da Silva LÓPEZ
André Luiz Franco SAMPAIO
Marcelo Raul Romero TAPPIN
Elba Pinto da Silva BON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fundacao Oswaldo Cruz
Original Assignee
Fundacao Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo Cruz filed Critical Fundacao Oswaldo Cruz
Priority to US15/504,898 priority Critical patent/US20170260121A1/en
Priority to EP15833187.6A priority patent/EP3184503A4/en
Priority to CN201580044795.9A priority patent/CN106660927A/zh
Publication of WO2016026014A1 publication Critical patent/WO2016026014A1/pt
Publication of WO2016026014A8 publication Critical patent/WO2016026014A8/pt
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/16—Unsaturated compounds
    • C07C61/22—Unsaturated compounds having a carboxyl group bound to a six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/16—Preparation of carboxylic acids or their salts, halides or anhydrides by oxidation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41—Preparation of salts of carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

A presente invenção proporciona um composto do ácido perílíco em forma de sal possuindo a Fórmula lI, tendo a atividade anti-câncer, onde o contra-íon M* compreende metais alcalinos ou alcalinos terrosos, como Na* (sódio), K+ (potássio), Ca+2/2 (cálcio), etc. A invenção contempla ainda um processo de obtenção do composto, uma composição farmacêutica, uso do composto e um método de tratamento de câncer.
PCT/BR2015/000127 2014-08-20 2015-08-20 Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer Ceased WO2016026014A1 (pt)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/504,898 US20170260121A1 (en) 2014-08-20 2015-08-20 Compound, process for preparing a compound, pharmaceutical composition, use of a compound and method for treating cancer
EP15833187.6A EP3184503A4 (en) 2014-08-20 2015-08-20 Perillic acid derivative, method for preparing a perillic acid derivative, pharmaceutical composition, use of a perillic acid derivative and cancer treatment method
CN201580044795.9A CN106660927A (zh) 2014-08-20 2015-08-20 紫苏酸衍生物、用于制备紫苏酸衍生物的方法、药物组合物、紫苏酸衍生物的用途及癌症治疗方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102014020443A BR102014020443A2 (pt) 2014-08-20 2014-08-20 composto, processo para preparação de um composto, composição farmacêutica, uso de um composto e método de tratamento de câncer
BR1020140204431 2014-08-20

Publications (2)

Publication Number Publication Date
WO2016026014A1 WO2016026014A1 (pt) 2016-02-25
WO2016026014A8 true WO2016026014A8 (pt) 2016-05-19

Family

ID=55350025

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2015/000127 Ceased WO2016026014A1 (pt) 2014-08-20 2015-08-20 Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer

Country Status (5)

Country Link
US (1) US20170260121A1 (pt)
EP (1) EP3184503A4 (pt)
CN (1) CN106660927A (pt)
BR (1) BR102014020443A2 (pt)
WO (1) WO2016026014A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113801899A (zh) * 2021-09-17 2021-12-17 厦门茂升教育科技有限公司 一种利用解脂耶氏酵母菌转化柠檬烯生成紫苏酸的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470877A (en) * 1992-04-09 1995-11-28 Wisconsin Alumni Research Foundation Uses of perillic acid methyl ester
DE19644422C2 (de) * 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen

Also Published As

Publication number Publication date
EP3184503A1 (en) 2017-06-28
WO2016026014A1 (pt) 2016-02-25
BR102014020443A2 (pt) 2016-03-29
US20170260121A1 (en) 2017-09-14
EP3184503A4 (en) 2018-02-14
CN106660927A (zh) 2017-05-10

Similar Documents

Publication Publication Date Title
PH12019500480A1 (en) Pyridine compound
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
WO2017070616A3 (en) Sexually transmitted disease vaccines
WO2016014927A3 (en) Crystalline form of nicotinamide riboside
NZ707859A (en) Inhibitors of sodium glucose cotransporter 1
MX2017014035A (es) Formas solidas novedosas.
MX2015011245A (es) Un inhibidor de mdm2 derivado de acido benzoico para el tratamiento del cancer.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MD20150091A2 (ro) Compuşi antivirali
TN2014000122A1 (en) 1 - arylcarbonyl - 4 - oxy - piperidine compounds useful for the treatment of neurodegenerative diseases
MX2017001620A (es) Formas cristalinas de inhibidores de glutaminasa.
PH12016502293A1 (en) Naphthyridinedione derivatives
WO2014035846A3 (en) Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
WO2012017448A3 (en) Salts of lapatinib
MX2017008074A (es) DERIVADOS DE IMIDAZOPIRIDAZINA COMO INHIBIDORES DE FOSFOINOSITIDA-3-QUINASAS BETA (PI3Kß).
AU2015280874A1 (en) Novel heterocyclic compound
WO2016026014A8 (pt) Derivado de ácido perílico, processo para a preparação de um derivado de ácido perílico, composição farmacêutica, uso de um derivado de ácido perílico e método de tratamento de câncer
EP2575465A4 (en) Raltegravir SALTS
WO2017106367A8 (en) Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
MX2017008076A (es) DERIVADOS DE IMIDAZOPIRIDAZINA ENLAZADOS A HETEROCICLILO COMO INHIBIDORES DE PI3Kß.
MY178017A (en) A salt of cephalosporin derivative, its crystalline solid and a method of manufacturing thereof
CA2901220C (en) Substituted chroman-6-yloxy-cycloalkanes and their use as pharmaceuticals
PH12016501215A1 (en) Azaindole derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15833187

Country of ref document: EP

Kind code of ref document: A1

REEP Request for entry into the european phase

Ref document number: 2015833187

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015833187

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 15504898

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WD Withdrawal of designations after international publication

Designated state(s): BR